Profile data is unavailable for this security.
About the company
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.
- Revenue in AUD (TTM)35.19k
- Net income in AUD-229.15m
- Incorporated1984
- Employees5.00
- LocationOpthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
- Phone+61 39826-0399
- Fax+61 39824-0083
- Websitehttps://opthea.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dimerix Ltd | 5.91m | -13.25m | 285.19m | 0.00 | -- | 21.25 | -- | 48.22 | -0.0239 | -0.0239 | 0.0106 | 0.0224 | 0.096 | -- | 22.53 | -- | -21.50 | -48.20 | -27.12 | -68.49 | -- | -- | -224.08 | -932.89 | -- | -- | 0.0072 | -- | 913.54 | 365.69 | 22.39 | -- | -- | -- |
| Cogstate Ltd | 78.92m | 15.17m | 392.86m | 61.00 | 26.44 | 5.41 | 20.08 | 4.98 | 0.0866 | 0.0866 | 0.4498 | 0.4233 | 0.8722 | -- | 4.88 | -- | 16.76 | 11.82 | 20.90 | 16.38 | 56.47 | 56.32 | 19.22 | 14.87 | -- | -- | 0.008 | 6.89 | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Racura Oncology Ltd | 788.42k | -4.79m | 448.72m | -- | -- | 26.80 | -- | 569.13 | -0.0282 | -0.0282 | 0.0043 | 0.0922 | 0.0418 | -- | 11.64 | -- | -25.38 | -41.75 | -27.84 | -44.07 | -- | -- | -607.20 | -2,015.76 | -- | -- | 0.00 | -- | -5.30 | 142.92 | 65.36 | -- | -- | -- |
| Immutep Ltd | 4.13m | -83.92m | 567.38m | 19.00 | -- | 5.74 | -- | 137.30 | -0.0573 | -0.0573 | 0.0028 | 0.0671 | 0.0251 | -- | 0.26 | -- | -50.93 | -32.47 | -61.41 | -34.65 | -- | -- | -2,030.67 | -21,963.05 | -- | -- | 0.0121 | -- | -49.76 | -62.18 | -43.82 | -- | 69.56 | -- |
| Opthea Ltd | 35.19k | -229.15m | 820.79m | 5.00 | -- | -- | -- | 23,323.44 | -0.1876 | -0.1876 | 0.00003 | -0.2299 | 0.0002 | -- | 0.1324 | -- | -132.57 | -123.14 | -- | -214.28 | -- | -- | -651,164.00 | -159,023.40 | -- | -11.15 | -- | -- | -79.95 | -15.80 | 26.09 | -- | 38.73 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -64.30m | 1.34bn | -- | -- | 12.86 | -- | -- | -0.2011 | -0.2011 | 0.00 | 0.2807 | 0.00 | -- | -- | -- | -50.27 | -40.38 | -54.18 | -43.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.91 | -- | 65.99 | -- |
| PYC Therapeutics Ltd | 24.52m | -47.56m | 1.94bn | 23.00 | -- | 6.11 | -- | 79.27 | -0.0836 | -0.0836 | 0.0429 | 0.2464 | 0.2157 | -- | 1.09 | -- | -42.46 | -42.88 | -47.19 | -47.98 | -- | -- | -196.86 | -172.76 | -- | -25.46 | 0.0056 | -- | 14.51 | 58.66 | -33.34 | -- | 55.85 | -- |
| Mesoblast Ltd | 24.21m | -143.78m | 2.89bn | 81.00 | -- | 3.41 | -- | 119.39 | -0.119 | -0.119 | 0.02 | 0.6571 | 0.0237 | -- | 2.25 | 298,875.80 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Telix Pharmaceuticals Ltd | 1.13bn | -10.03m | 3.39bn | 1.12k | -- | 5.79 | 167.35 | 2.99 | -0.0297 | -0.0297 | 3.35 | 1.73 | 0.7639 | 13.90 | 7.44 | 1,010,240.00 | -0.6772 | -4.82 | -0.8545 | -6.41 | 47.51 | 55.04 | -0.8864 | -5.75 | 1.27 | 3.64 | 0.5293 | -- | 55.61 | 195.18 | -121.15 | -- | 202.38 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 05 Sep 2025 | 321.14m | 0.00% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 43.24m | 0.00% |
| BlackRock Asset Management North Asia Ltd.as of 31 Oct 2025 | 3.78m | 0.00% |
| Pictet Asset Management SAas of 30 Jun 2025 | 2.59m | 0.00% |
| Charles Schwab Investment Management, Inc.as of 05 Feb 2026 | 2.28m | 0.00% |
| Vanguard Fiduciary Trust Co.as of 31 Jan 2026 | 1.33m | 0.00% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 1.05m | 0.00% |
| Russell Investment Management Ltd.as of 30 Jan 2026 | 813.55k | 0.00% |
| Vanguard Asset Management Ltd.as of 31 Jan 2026 | 291.32k | 0.00% |
| Vanguard Global Advisers LLCas of 31 Jan 2026 | 232.40k | 0.00% |
